We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. Read More
President Biden yesterday revived a travel ban aimed at preventing the mutated strain of SARS-CoV-2 coronavirus first detected in South Africa from reaching the U.S. — and Moderna said it will launch a trial to evaluate a booster shot meant to provide additional protection against the mutated strain. Read More
Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. Read More
Eli Lilly reported yesterday that its monoclonal antibody bamlanivimab (LY-CoV555) significantly lessened the risk of contracting COVID-19 among nursing home residents and staff, according to findings from a phase 3 trial. Read More
Merck announced that it is ending a phase 3 study evaluating its immunotherapy bintrafusp alfa in patients with stage IV non-small-cell lung cancer, following disappointing efficacy results. Read More
Beyond COVID-19 and other viral infections, PAD4 inhibitors also show potential for treating autoimmune disorders, such as rheumatoid arthritis, the company said. Read More
The booster-shot study aims to assess the safety of an extra shot given a year after the second dose and the additional immune response it elicits. Read More